Artiva details wind-down cost estimates after scrapping AlloNK program
The company now pegs total charges from its workforce cut and trial shutdown at $27 million to $35 million, with most costs expected in Q4 2026.
Artiva Biotherapeutics filed a Form 8-K/A on November 9, 2026 to amend an earlier disclosure about the discontinuation of its AlloNK (AB-101) program. The original filing, made October 27, 2026, disclosed that the company's board approved discontinuing development of AlloNK (AB-101), its non-genetically modified, allogeneic natural killer cell therapy candidate, as part of a process to explore strategic alternatives, including a plan to cut the workforce by approximately 94% of current employees1.
At the time of that original filing, Artiva said it could not yet make a good faith estimate of the costs and charges it would incur from the wind down1. The amendment fills in those numbers.
Artiva now estimates $10 million to $15 million in contract termination and other costs tied to shutting down its AlloNK clinical trials, plus $17 million to $20 million in workforce reduction costs covering severance, benefits, payroll taxes and other termination expenses.1
On timing, the company expects to complete the workforce reduction in the first quarter of 2027, with most wind-down costs falling in the fourth quarter of 2026.1
Artiva cautioned that it may incur additional charges or cash expenditures not currently contemplated, depending on events tied to the wind down1, and noted that the cost and timing estimates rest on a number of assumptions and actual results may differ1.
The filing was signed by Chief Executive Officer Fred Aslan, M.D., dated November 9, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.